BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35940512)

  • 21. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis.
    Khosravi N; Stoner L; Farajivafa V; Hanson ED
    Brain Behav Immun; 2019 Oct; 81():92-104. PubMed ID: 31454519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer.
    Demark-Wahnefried W; Nix JW; Hunter GR; Rais-Bahrami S; Desmond RA; Chacko B; Morrow CD; Azrad M; Frugé AD; Tsuruta Y; Ptacek T; Tully SA; Segal R; Grizzle WE
    BMC Cancer; 2016 Feb; 16():61. PubMed ID: 26850040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
    Stearns V; Yamauchi H; Hayes DF
    Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
    Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
    Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical usefulness of circulating tumor markers].
    Ohkura H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer.
    Abramson VG; Mayer IA
    Curr Treat Options Oncol; 2011 Dec; 12(4):403-11. PubMed ID: 21918859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
    Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
    Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer].
    Letiagin VP; Vysotskaia IV
    Vestn Ross Akad Med Nauk; 1995; (4):10-4. PubMed ID: 7780332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological markers in breast cancer prognosis and treatment.
    Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
    J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting the molecular pathways involved in the effects of physical activity on breast cancers cells: A narrative review.
    Orlandella FM; De Stefano AE; Iervolino PLC; Buono P; Soricelli A; Salvatore G
    Life Sci; 2021 Jan; 265():118790. PubMed ID: 33220294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the breast ductal system in the diagnosis of cancer (review).
    Shao ZM; Liu Y; Nguyen M
    Oncol Rep; 2001; 8(1):153-6. PubMed ID: 11115588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era.
    Zhang L; Yu X; Zhou L; Yang Y; Liu S
    J BUON; 2018; 23(5):1316-1324. PubMed ID: 30570853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen.
    Hwang H; Kim J; Choi J; Kim KH; Han HS
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.